Mouse siTrio from B-Bridge International

...pathic effect inhibition assays, also known as CPE...ue culture supernatents; serum from PK studies and... is defined as the quantity of interferon required... viral infection by 50%. All standards used in o...

Topoisomerase I from Invitrogen

... type I eukaryotic topoisomerase that removes both...lled right- and left-handed supercoils) from coval... covalently closed, circular DNA with fewer positi...se I does not absolutely require Mg 2+ to functio...

Eco RII (Bst NI) from Roche Applied Science

Biology Products:

Human Interferon Alpha Bioassay Services from PBL InterferonSource Topoisomerase I from Invitrogen Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies Eco RII (Bst NI) from Roche Applied Science

(Date:11/30/2009)...s of The Journal of Experimental Biology are ple... National de la Recherche Scientifique (CNRS) in t...r of this year,s JEB Outstanding Paper Prize. ,T...ng achievement and is intended to encourage young ...-in-Chief, and adds that ,we truly appreciate when...

(Date:11/30/2009)...led invasion proteins are crucial for infection. E...man cells, which stimulates the host cell to take ...s exert a different function, for example the regu...,s results have now been published in the current ... Spoiled meat is one of the sources for Listeria ...

(Date:11/30/2009)...tage of lower early bird registration rates and re...ngress of 2010 at http://www.iofwco-ecceo10.org/ ... the International Osteoporosis Foundation (IOF) a...Aspects of Osteoporosis and Osteoarthritis (ESCEO)...ld are expected to attend. The exciting scientific...

Breaking Biology News(10 mins):French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2 French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3 French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4 It takes 2 to infect 2 Happier healthier more productive hens on omega 3 3F 9233 1 Happier healthier more productive hens on omega 3 3F 9233 2 Secure eHealth and DRM Security Partner to Provide Most Secure Healthcare Network Available 51456 1 Secure eHealth and DRM Security Partner to Provide Most Secure Healthcare Network Available 51456 2 Secure eHealth and DRM Security Partner to Provide Most Secure Healthcare Network Available 51456 3 Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 1 Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 2 Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 3 Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 4

[1] French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 [0] It takes 2 to infect [0] Register now online for the World Congress on Osteoporosis 2010 -- IOF WCO-ECCEO10

...nternational clinical trial, a new drug that selec...tive in preventing acute kidney transplant rejecti...eatment. , Patients who took the experimental dru...29Y), also had better kidney function and experien... standard anti-rejection drugs, including kidney d...

...sts have tracked down the biological trigger that ...sfiguring bone disorder that can cause blindness a...g-range gene regulation and could lead to new trea...isorders. , A research team from Lawrence Livermor... Novartis Institutes for BioMedical Research in Sw...

...of the first molecular studies of the human antibo... Institute (HHMI) researchers and their colleagues... immune systems need to spot and quash this often-...p scientists improve the existing vaccine, which h...en, an HHMI international research scholar and ass...

Other Biology News:New type of rejection blocker protects kidneys after transplant 2 New type of rejection blocker protects kidneys after transplant 3 New type of rejection blocker protects kidneys after transplant 4 Researchers track down cause of a disfiguring bone disorder 2 Researchers track down cause of a disfiguring bone disorder 3 Fragment of yellow fever virus may hold key to safer vaccine 2 Fragment of yellow fever virus may hold key to safer vaccine 3

New type of rejection blocker protects kidneys after transplant Researchers track down cause of a disfiguring bone disorder Fragment of yellow fever virus may hold key to safer vaccine

(Date:12/2/2009)... SINGAPORE, Dec. 2 S*BIO Pte Ltd t...l JAK2 inhibitor, SB1518, at The American Society ...n New Orleans. ,, Data will be presented on the... trial of SB1518 detailing its safety, tolerabilit...ile in dose levels ranging from 100 to 600 mg. The...

(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world ...in turmoil and uncertainty is part of many,busines...ndustry has been,relatively immune to the economic.... , During the midst of the difficult tim...p; Johnson inaugurated an R&D center in Shangh...

(Date:12/1/2009)...E VILLAGE, Nev., Dec. 1 ...nnounced revenue guidance for the fourth quarter e...n, as compared with $69 million for the fourth qua...lts was the first of two installment payments of $...h quarter 2008 results was a one-time $1.8 million...

(Date:12/1/2009)...UTH, Mass., Dec. 1 Harvest Technol...y results from the company sponsored 60-patient cl...Center in Chennai, India using the company,s BMAC ...Critical Limb Ischemia (CLI). Sri Ramachandra Medi...ciated institution based in Chennai, India and one...

Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4 S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5 Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2 Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3 PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2 PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3 Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2 Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3

[0] S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders [0] Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit [0] PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million [0] Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia

Products	Mouse siTrio from B-Bridge International
Company	B-Bridge International
Item	Mouse siTrio
Price	$585.00
Description	siTrio siRNA --- a cocktail of 3 siRNAs specifically targeted to your target gene of interestis our most popular product. The siTrio reagent guarantees you get more than 75% knockdown of your target gene when used under standard conditions (100 nM siRNA for transfection and confirmation of optimal transfection with one of B-Bridges controls). To ensure knockdown, use siTrio siRNA.
Info	B-Bridge International 320 Logue Avenue Mountain View, CA 94043 Customer Service: 650-969-7727 Fax Number: 650-969-7737 Web Site: http://www.b-bridge.com